Accelerating Retrospective Image Collection with Enhanced PHI De-identification
In retrospective imaging studies, sites are typically responsible for manually anonymizing images before transfer, causing delays of up to two weeks per request. This can prolong the data collection timeline and introduce inconsistencies in de-identification across sites. This also produces regulatory risk and an increased burden on clinical sites.
Implementing an automated PHI de-identification module integrated within the imaging platform allows for real-time removal of protected health information (PHI) while preserving essential imaging metadata.
3 key questions that are answered:
- What role do DICOM headers play in imaging, and what kind of Protected Health Information can be found within them?
- What is a retrospective vs. a prospective study, and what unique challenges do sites face when participating in these types of studies?
- How can turnaround time be reduced and processes streamlined for efficient collection of images in all stages of clinical trials?
Satej BhogillOncology Associate, MERIT
Satej specializes in central review imaging for clinical trials on the West Coast. With experience working alongside CROs, sponsors, and research teams, Satej plays a key role in ensuring seamless imaging workflows that support high-quality oncology research.
Sally Asad, MPHOncology Project Manager
Sally Asad is a Project manager in the Oncology division at MERIT and a public health professional with a background in clinical research and business development. She earned her master’s in public health from the University of North Texas Health Science Center where she gained experience and insight working in the Oncology department of one of the largest hospitals in Dallas. In her role as an Oncology Project Manager, Sally oversees the execution of clinical studies from start-up through closeout while working closely with sponsors, ensuring efficiency and compliance. She is committed to advancing novel therapies and contributing to the development of new treatments for patients.
Alyssa Bartholomew BS R.T. (R)(CT)(MR)IMAGING QUALITY CONTROL SPECIALIST II, ONCOLOGY
Alyssa works at MERIT as an Oncology Imaging Quality Control Specialist II. She is certified in general radiology, Computed Tomography (CT) and Magnetic Resonance Imaging (MRI), and has over a decade of experience with advanced imaging at outpatient imaging facilities, University research centers and hospitals. At MERIT, Alyssa ensures imaging parameters and protocol requirements are adhered to in radiographic exams that are submitted through our EXCELSIORTM software. She is instrumental in supporting study sites and ensuring the image collection and quality control process runs smoothly. Alyssa is passionate about clinical trials and the advancement of cancer research through radiologic imaging modalities.